Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder
Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder
复制标题
DOI：
10.1016/j.jaac.2016.02.016
复制
发表时间：
2016-05-01
影响因子：
13.3
通讯作者：
Vitiello, Benedetto
中科院分区：
文献类型：
--
作者：
Scahill, Lawrence;Jeon, Sangchoon;Vitiello, Benedetto
目的：研究利培酮单一治疗对孤独症谱系障碍(ASD)儿童体重增加和代谢的影响。方法：对124例有严重行为问题的ASD儿童(平均年龄6.9±2.35岁；男105例，女19例)进行为期24周的多点随机对照试验。在试验期间，我们监测了身高、体重、腰围和不良反应。结果：97名儿童平均服用利培酮22.9+/-2.8周，24周体重增加5.4+/-3.4公斤(P
Objective: We examine weight gain and metabolic consequences of risperidone monotherapy in children with autism spectrum disorder (ASD).Method: This was a 24-week, multisite, randomized trial of risperidone only versus risperidone plus parent training in 124 children (mean age 6.9 +/- 2.35 years; 105 boys and 19 girls) with ASD and serious behavioral problems. We monitored height, weight, waist circumference, and adverse effects during the trial. Fasting blood samples were obtained before treatment and at week 16.Results: In 97 children with a mean of 22.9 +/- 2.8 weeks of risperidone exposure, there was a 5.4 +/- 3.4 kg weight gain over 24 weeks (p